Table 2. Clinical and laboratory characteristics of study group 1.
| Feature | All patients (n = 51) | UDCA respondersa (n = 21) | UDCA non-respondersa (n = 18) | p valueb |
|---|---|---|---|---|
| Age (years) | 60.4 ± 11.1 | 62.2 ± 14.3 | 60.3 ± 9.1 | 0.6 |
| Gender (F/M) | 45/6 | 20/1 | 15/3 | 0.43 |
| Cirrhosis (yes/no) | 23/28 | 8/13 | 12/6 | 0.06 |
| Hemoglobin (mg/dl) | 13.1 ± 1.5 | 13.7 ± 1.3 | 12.2 ± 1.5 | 0.02 |
| ALT (IU/l; Normal:<30) | 71.4 ± 131.0 | 88.6 ± 194.5 | 58.7 ± 37.9 | 0.49 |
| AST (IU/l; Normal:<30) | 60.8 ± 57.6 | 55.7 ± 75.2 | 74.7 ± 47.1 | 0.33 |
| ALP (IU/l; Normal:<120) | 196.7 ± 149.1 | 111.2 ± 44.5 | 278.9 ± 149.4 | 0.0003 |
| GGT (IU/l; Normal:<42) | 219.3 ± 331.8 | 72.8 ± 57.7 | 271.4 ± 232.8 | 0.06 |
| Bilirubin (mg/dl; Normal:<1.0) | 1.81 ± 4.5 | 1.1 ± 1.4 | 2.9 ± 6.8 | 0.23 |
| Albumin (g/dl; Normal:3.8–4.4) | 4.1 ± 0.5 | 4.3 ± 0.4 | 3.8 ± 0.4 | 0.002 |
| INR (Normal: 0.8–1.2) | 1.1 ± 0.3 | 1.1 ± 0.1 | 1.2 ± 0.4 | 0.06 |
| Mayo Risk Score for PBC | 5.4 ± 1.6 | 5.0 ± 1.4 | 6.1 ± 1.9 | 0.04 |
| Serum FGF19 (pg/ml) | 104.0 ± 152.5 | 67.5 ± 42.9 | 167.0 ± 240.3 | 0.04 |
Values are given as mean ± SD, unless stated otherwise.
Abbreviations: PBC-primary biliary cirrhosis, FGF19 – fibroblast growth factor 19.
aIn 12 patients UDCA response status was not available.
bp values: UDCA responders vs non-responders.